What question did this study set out to answer?

P0970Efficacy and safety of upadacitinib in ulcerative colitis after prior tofacitinib exposure: real-world data from Colombia

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the efficacy and safety of upadacitinib in ulcerative colitis patients with prior tofacitinib exposure.
Conducted a retrospective, multicenter analysis
Included adults with moderate to severe ulcerative colitis
Administered upadacitinib at 45 mg/day for induction and 30 mg/day for maintenance
Assessed clinical and biochemical responses at 16 weeks and 6 months
Compared outcomes between patients with and without prior tofacitinib exposure using statistical methods.
81.2% of patients achieved clinical response at week 16
61.7% reached clinical remission; 46.8% achieved steroid-free remission
At 6 months, remission persisted in 55.3% of patients
Prior tofacitinib use did not significantly impact clinical outcomes
Adverse events were mostly mild, with no serious complications reported.

No takes yet. Share an insight, caveat, or question.

A multicenter study demonstrates upadacitinib's effectiveness in ulcerative colitis patients post-tofacitinib, suggesting a viable treatment option.

Izquierdo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

A multicenter study demonstrates upadacitinib's effectiveness in ulcerative colitis patients post-tofacitinib, suggesting a viable treatment option.